HPLC determination of thiopurine nucleosides and nucleotides in vivo in lymphoblasts following mercaptopurine therapy.
BACKGROUND
Mercaptopurine is a prodrug requiring intracellular activation to thiopurine nucleotides to exert antileukemic effect. We developed a reversed-phase liquid chromatographic assay for the quantification of mercaptopurine, thioguanine, and methylmercaptopurine nucleoside and nucleotide concentrations in the target tissue, the leukemic lymphoblast.


METHODS
Leukemic blasts were isolated from peripheral blood and bone marrow by a standard Ficoll-hypaque procedure. Proteins were removed by ultrafiltration in the presence of dithiothreitol. Thiopurine ribonucleotides were converted into their respective ribonucleosides by treatment of ultrafiltrate with acid phosphatase. Thiopurine nucleosides and bases were measured by direct injection of ultrafiltrate into the chromatographic system. Thiopurine nucleotide concentrations were calculated by subtracting the thiopurine nucleoside concentrations measured after treatment with acid phosphatase from those measured after direct injection of ultrafiltrate in the chromatographic system. Analytes were separated on a C18 Supelco column with ammonium phosphate-methanol eluent coupled with ultraviolet detection.


RESULTS
CVs for intra- and interday precision were 1.1-14% (median, 4.9%), and recovery of added analyte was 89-126% (median, 105%) at low and high concentrations of analytes, except for mercaptopurine riboside. The median signal for each of the five metabolites in lymphoblast samples was 98% (range, 80-106%) of that in water. Detection limits for thiopurine bases and nucleosides ranged from 0.5 to 4.5 pmol/5 x 10(6) cells.


CONCLUSIONS
This method is suitable for measurement of thiopurine metabolite concentrations in lymphoblasts in children with acute lymphoblastic leukemia following a single dose of intravenous mercaptopurine.
Dervieux
Thierry
T
Department of. Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, TN 38105, USA.
Chu
Yaqin
Y
Su
Yi
Y
Pui
Ching-Hon
CH
Evans
William E
WE
Relling
Mary V
MV
D000964:Antimetabolites, Antineoplastic / Q000097:blood / Q000627:therapeutic use*; D002648:Child; D002851:Chromatography, High Pressure Liquid; D006801:Humans; D008214:Lymphocytes / Q000737:chemistry*; D015122:Mercaptopurine / Q000097:blood / Q000627:therapeutic use*; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000097:blood* / Q000188:drug therapy; D011355:Prodrugs / Q000378:metabolism / Q000627:therapeutic use*; D011684:Purine Nucleosides / Q000097:blood*; D011685:Purine Nucleotides / Q000097:blood*
D000964:Antimetabolites, Antineoplastic; D011355:Prodrugs; D011684:Purine Nucleosides; D011685:Purine Nucleotides; D015122:Mercaptopurine